A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination with Nivolumab in Subjects with Selected Advanced Solid Tumors
This study is being done to test the good and bad effects of BMS-986158 as monotherapy and in combination with nivolumab in patients with select advance tumors.
Triple negative breast (TNBC)
Small cell lung cancer (SCLC)
Non small cell lung cancer (NSCLC)
Neuroendocrine prostate cancer
Renal Cell Carcinoma (RCC)
1. Men and women 18 years or older
2. Recurrent or metastatic solid tumors
3. Adequate organ function
4. Other criteria apply
18 - 89
Healthy Volunteers Needed
Duration of Participation
You will receive the study drug as long as you and the investigator feel that you are tolerating the study drug and your disease is not getting worse. After you finish treatment, your doctor will continue to watch you for side effects and follow your condition every 3 months.
Knight Clinical Trials Information Line